

# IN VIVO STUDIES ON VIRAL VIRULENCE

---

M.Phil student: Emily TSUI


Supervisor : Professor Paul K.S Chan

Department of Microbiology, CUHK

Date: 15th Dec, 2014

# Viral Virulence


- Capacity of a virus to cause disease in a host
- Virulent vs avirulent or attenuated virus
  - A virulent strain causes significant disease
  - An avirulent or attenuated strain causes no or reduced disease



- Virulence factors & mechanisms
- Virus-induced immune suppression
- Pathogenesis

# *In vitro* Studies

- *In vitro*: taking place in a test tube, culture dish or elsewhere OUTSIDE a living organism
- Cell lines, primary cells
- Assaying genes for essentiality to invasion, survival, replication, immune modulation and cytotoxicity



## Multiple Virulence Determinants of Foot-and-Mouth Disease Virus in Cell Culture

ERIC BARANOWSKI,<sup>1</sup> NOEMI SEVILLA,<sup>1†</sup> NURIA VERDAGUER,<sup>2</sup>  
CARMEN M. RUIZ-JARABO,<sup>1</sup> EWALD BECK,<sup>2</sup>  
AND ESTEBAN DOMINGO<sup>1\*</sup>

*Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Universidad Autónoma de Madrid, 28049 Madrid,<sup>1</sup> and Centre de Investigació i Desenvolupament (C.S.I.C.), 08028 Barcelona,<sup>2</sup> Spain, and Institut für Biochemie, University of Giessen, D-35392 Giessen, Germany<sup>2</sup>*

Received 15 January 1998/Accepted 30 April 1998


# *In vitro* Studies

- Excellent tools for simple questions with limited variables
- Cells are easily manipulated
- Cost efficient
- Scalable


*In vitro* studies have given us a lot BUT...

- Focus on one specific aspect of the disease process only
- Cannot predict relevant phenotypes associated with pathogenesis

# Models Systems to Study Viral Virulence: *In vitro* and *In vivo*



- *In vitro*: cell lines, primary cells



- *In vivo*: animals models



Mice with new receptors

Mice with complete viral genomes

Mice expressing individual viral genes

Study of virus infection and disease



A photograph of a white mouse, shown in profile, facing right. The mouse is standing on a light-colored surface. The image is framed within a rounded rectangular box that is part of a larger diagram.

Study of the host response to infection


Clonal T-cell receptor

Immune mediator deletion

Immune cell deletion

Immune mediator overproduction

- Human viruses in animals
  - May need to manipulate the mouse
  - E.g. Transgenic poliovirus receptor mouse
- Animal viruses that resemble human infection



human receptor to poliovirus  
(hPVR)




Transgenic poliovirus receptor mouse  
(TgPVR)

# Virulence can be Quantitated

- Meantime to death
- Meantime to appearance of symptoms
- Measurement of fever, weight loss
  - Influenza infection
- Measurement of pathological lesions
  - Poliovirus infection
- Reduction in blood CD4+ lymphocytes
  - HIV-1 infection

# General Approach







What makes type 2 virus more virulence than type 1?  
Are there any genetic differences that affect viral virulence?


# Virulence Genes

- Major goal of virology is to identify virulence genes that determine virulence
- Viral virulence genes involved in
  - Viral replication
  - Defeat host defense mechanisms
  - Invasiveness
  - Intrinsic cell killing effects

- Virulence genes usually identified by mutation: a virus that causes reduced or no disease in a specified system


Virus	Growth in cell culture	Effect on mice	Virulence phenotype
Wild type		 <p>Replication</p>	Neurovirulent
Mutation leading to a general defect in replication		 <p>Poor replication</p>	Attenuated
Mutation in a gene specifically required for virulence		 <p>Poor replication</p>	Attenuated

# Virulence determinant in Poliovirus



- Poliovirus replication in mouse brain

Virus	Base at 472	LD <sub>50</sub>
PRV7.3	U	$>2 \times 10^7$
PRV8.4	C	$9 \times 10^3$



- One base change is enough to change the virulence of poliovirus
- Implication: develop oral polio vaccine (OPV)

# Other Factors Affecting Viral Virulence in Mice

- Dose
- Route of infection
- Age of host

Virus	No. of virions needed to kill 50% of animals			
	Suckling mice		Adult mice	
	Intracerebral infection	Subcutaneous infection	Intracerebral infection	Subcutaneous infection
Wild-type La Crosse virus	-1	-1	-1	-10
Attenuated La Crosse virus mutant	-1	$>10^6$	$>10^6$	$>10^7$

- Species
- Gender (males slightly more susceptible to viral infections than females)

Age of host

Gender

Species

**Animal experiments.** Five- to 6-wk-old female BALB/c mice were obtained from a commercial supplier (Charles River Laboratories, Wilmington, Massachusetts, United States). All mice were housed in cages and allowed to acclimatize for 5 days prior to use in experiments.

Route of inoculation

Dose

To assay virulence, groups of three to six mice were each inoculated i.p. at two different sites with 10 FFU of virus in 0.1 ml of DMEM. Following infection, mice were observed daily for clinical symptoms and their weights were recorded for 11 d postinoculation. All surviving animals were observed for at least 21 d (three times the average duration of survival of the control animals).

The  $MLD_{50}$  was determined by i.p. inoculation of mice (three to six per group) with serial 10-fold dilutions of virus and monitoring of the survival rates.

To assess virus growth characteristics in mice, groups of 12 animals were inoculated i.p. with 5 FFU of virus (corresponds to approximately 500  $MLD_{50}$  for MA-ZEBOV). On days 1, 2, 3, and 5 postinfection, spleen, liver, and blood were collected from three infected mice, and the spleen and liver samples were homogenized. Viral infectivity titers were determined by use of a focus-forming assay in Vero E6 cells [36].

# Benefits and Problems of Using Animal Model

## Benefits

- Show human-like clinical signs and pathology of disease
- Suitable for transmission experiments, vaccine research
- Helps to understand some certain mechanism of disease and therapeutic agent observed in animal model.

## Problems

- Practical considerations
- Absence of small animal model
- Never mimics exactly what happens in people

# Future Prospects

- To increase knowledge of molecular mechanism of virus replication and mechanism of pathogenesis in viral disease further.
- To investigate antibody enhancement of virus infection, induction of auto immunity and development of immune cell dysfunction and tumours
- To develop in the field of small animal models
- Efficacy assessment and pre-clinical evaluation of novel virus vaccine constructs

## Molecular Determinants of Ebola Virus Virulence in Mice

Hideki Ebihara<sup>1,2,3</sup>, Ayato Takada<sup>2,4</sup>, Darwyn Kobas  
Mike Bray<sup>9</sup>, Heinz Feldmann<sup>3,8</sup>, Yoshihiro Kawaoka

## PB1-mediated virulence attenuation of H5N1 influenza virus in mice is associated with PB2

Jing Li,<sup>†</sup> Yongqiang Li,<sup>†</sup> Yi Hu, Guohui Chang, Wei Sun, Yinhui Yang,  
Xiaoping Kang, Xiaoyan Wu and Qingyu Zhu

## The Virulence of 1997 H5N1 Influenza Viruses in the Mouse Model Is Increased by Correcting a Defect in Their NS1 Proteins<sup>v</sup>

April Spesock,<sup>1,4†</sup> Meghana Malur,<sup>2†</sup> M. Jaber Hossain,<sup>1,4</sup> Li-Mei Chen,<sup>1</sup> Bradley L. Njaa,<sup>3</sup>  
Charles T. Davis,<sup>1</sup> Aleksandr S. Lipatov,<sup>1</sup> Ian A. York,<sup>1</sup>  
Robert M. Krug,<sup>2\*</sup> and Ruben O. Donis<sup>1\*</sup>

## Heterogeneous virulence of pandemic 2009 influenza H1N1 virus in mice

Amber Farooqui<sup>1,2,3†</sup>, Alberto J. Leon<sup>1,3†</sup>, Yanchang Lei<sup>4</sup>, Pusheng Wang<sup>5</sup>,  
Wei Dong<sup>1</sup>, Salvatore Rubino<sup>2,6</sup>, Jie Lin<sup>5</sup>, Guishuang Li<sup>1</sup>, Zhen Zhao<sup>1</sup> and

## Mutations in the Envelope Protein of Japanese Encephalitis Virus Affect Entry Into Cultured Cells and Virulence in Mice

HITOSHI HASEGAWA,<sup>1</sup> MASAMICHI YOSHIDA, TAKAHIKO SHIOSAKA,  
SHI

## Influenza A Virus PB1-F2 Protein Contributes to Viral Pathogenesis in Mice

Dmitriy Zamarin, Mila B. Ortigoza, and Peter Palese<sup>\*</sup>

*Department of Microbiology, Mount Sinai School of Medicine, New York, New York 10029*

Received 27 February 2006/Accepted 30 May 2006

THANK YOU

---